Stockreport

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne [Yahoo! Finance]

Dermata Therapeutics, Inc.  (DRMA) 
PDF - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 - - Over 30 [Read more]